BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: He L, Ingram A, Rybak AP, Tang D. Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells. J Clin Invest 2010;120:2094-108. [PMID: 20458142 DOI: 10.1172/JCI40778] [Cited by in Crossref: 79] [Cited by in F6Publishing: 84] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Guo Y, He J, Zhang H, Chen R, Li L, Liu X, Huang C, Qiang Z, Zhou Z, Wang Y, Huang J, Zhao X, Zheng J, Chen GQ, Yu J. Linear ubiquitination of PTEN impairs its function to promote prostate cancer progression. Oncogene 2022. [PMID: 36192478 DOI: 10.1038/s41388-022-02485-6] [Reference Citation Analysis]
2 Wang G, Zhuang Z, Cheng J, Yang F, Zhu D, Jiang Z, Du W, Shen S, Huang J, Hua L, Chen Y. Overexpression of SHARPIN promotes tumor progression in ovarian cancer. Experimental and Molecular Pathology 2022. [DOI: 10.1016/j.yexmp.2022.104806] [Reference Citation Analysis]
3 Rackow AR, Judge JL, Woeller CF, Sime PJ, Kottmann RM. miR-338-3p blocks TGFβ-induced myofibroblast differentiation through the induction of PTEN. Am J Physiol Lung Cell Mol Physiol 2022;322:L385-400. [PMID: 34986654 DOI: 10.1152/ajplung.00251.2021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Wang G, Zhuang Z, Shen S, Yang F, Jiang Z, Liu Z, Wang T, Hua L. Regulation of PTEN and ovarian cancer progression by an E3 ubiquitin ligase RBCK1. Hum Cell 2022. [PMID: 35174471 DOI: 10.1007/s13577-022-00681-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Butt U, Khan MH, Pouwels J, Westermarck J. SHARPIN serine 146 phosphorylation mediates ARP2/3 interaction, cancer cell invasion and metastasis.. [DOI: 10.1101/2022.01.21.477220] [Reference Citation Analysis]
6 He J, Wang J, Li T, Chen K, Li S, Zhang S. SIPL1, Regulated by MAZ, Promotes Tumor Progression and Predicts Poor Survival in Human Triple-Negative Breast Cancer. Front Oncol 2021;11:766790. [PMID: 34976812 DOI: 10.3389/fonc.2021.766790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Asanomi Y, Shigemizu D, Akiyama S, Miyashita A, Mitsumori R, Hara N, Ikeuchi T, Niida S, Ozaki K. A functional variant of SHARPIN confers increased risk of late-onset Alzheimer's disease. J Hum Genet 2022;67:203-8. [PMID: 34737388 DOI: 10.1038/s10038-021-00987-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
8 Chai C, Wu HH, Abuetabh Y, Sergi C, Leng R. Regulation of the tumor suppressor PTEN in triple-negative breast cancer. Cancer Lett 2021;527:41-8. [PMID: 34902523 DOI: 10.1016/j.canlet.2021.12.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
9 Tu Z, Hou S, Zheng Y, Abuduli M, Onder T, Intlekofer AM, Karnoub AE. In vivo library screening identifies the metabolic enzyme aldolase A as a promoter of metastatic lung colonization. iScience 2021;24:102425. [PMID: 34036247 DOI: 10.1016/j.isci.2021.102425] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Nguyen Huu T, Park J, Zhang Y, Park I, Yoon HJ, Woo HA, Lee SR. Redox Regulation of PTEN by Peroxiredoxins. Antioxidants (Basel) 2021;10:302. [PMID: 33669370 DOI: 10.3390/antiox10020302] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
11 Gu Y, Chow MJ, Kapoor A, Lin X, Mei W, Tang D. Differential Expression of a Panel of Ten CNTN1-Associated Genes during Prostate Cancer Progression and the Predictive Properties of the Panel Towards Prostate Cancer Relapse. Genes (Basel) 2021;12:257. [PMID: 33578925 DOI: 10.3390/genes12020257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Tian M, Jiang X, Li X, Yang J, Zhang C, Zhang W. LKB1IP promotes pathological cardiac hypertrophy by targeting PTEN/Akt signalling pathway. J Cell Mol Med 2021;25:2517-29. [PMID: 33486894 DOI: 10.1111/jcmm.16199] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
13 Gu Y, Lin X, Kapoor A, Li T, Major P, Tang D. Effective Prediction of Prostate Cancer Recurrence through the IQGAP1 Network. Cancers (Basel) 2021;13:430. [PMID: 33498739 DOI: 10.3390/cancers13030430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Zeng C, Xiong D, Zhang K, Yao J. Shank-associated RH domain interactor signaling in tumorigenesis. Oncol Lett 2020;20:2579-86. [PMID: 32782575 DOI: 10.3892/ol.2020.11850] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
15 Lerche M, Elosegui-Artola A, Kechagia JZ, Guzmán C, Georgiadou M, Andreu I, Gullberg D, Roca-Cusachs P, Peuhu E, Ivaska J. Integrin Binding Dynamics Modulate Ligand-Specific Mechanosensing in Mammary Gland Fibroblasts. iScience 2020;23:100907. [PMID: 32106057 DOI: 10.1016/j.isci.2020.100907] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
16 Salvatore L, Calegari MA, Loupakis F, Fassan M, Di Stefano B, Bensi M, Bria E, Tortora G. PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target. Cancers (Basel) 2019;11:E1765. [PMID: 31717544 DOI: 10.3390/cancers11111765] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
17 Jiang Y, Lin X, Kapoor A, He L, Wei F, Gu Y, Mei W, Zhao K, Yang H, Tang D. FAM84B promotes prostate tumorigenesis through a network alteration. Ther Adv Med Oncol 2019;11:1758835919846372. [PMID: 31205500 DOI: 10.1177/1758835919846372] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
18 Ojo D, Rodriguez D, Wei F, Bane A, Tang D. Downregulation of CYB5D2 is associated with breast cancer progression. Sci Rep 2019;9:6624. [PMID: 31036830 DOI: 10.1038/s41598-019-43006-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
19 Bazzichetto C, Conciatori F, Pallocca M, Falcone I, Fanciulli M, Cognetti F, Milella M, Ciuffreda L. PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise? Cancers (Basel) 2019;11:E435. [PMID: 30925702 DOI: 10.3390/cancers11040435] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 14.0] [Reference Citation Analysis]
20 Siitonen R, Peuhu E, Autio A, Liljenbäck H, Mattila E, Metsälä O, Käkelä M, Saanijoki T, Dijkgraaf I, Jalkanen S, Ivaska J, Roivainen A. 68Ga-DOTA-E[c(RGDfK)]2 PET Imaging of SHARPIN-Regulated Integrin Activity in Mice. J Nucl Med 2019;60:1380-7. [PMID: 30850498 DOI: 10.2967/jnumed.118.222026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
21 Lerche M, Elosegui-artola A, Kechagia JZ, Guzmán C, Georgiadou M, Gullberg D, Roca-cusachs P, Peuhu E, Ivaska J. Integrin binding dynamics modulate ligand-specific mechanosensing in mammary gland fibroblasts.. [DOI: 10.1101/570721] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
22 Liang Y, Chen B, Liu F, Wang J, Yang Y, Zheng Y, Tan S. Shank-associated RH domain-interacting protein expression is upregulated in entodermal and mesodermal cancer or downregulated in ectodermal malignancy. Oncol Lett 2018;16:7180-8. [PMID: 30546455 DOI: 10.3892/ol.2018.9514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Naderali E, Khaki AA, Rad JS, Ali-Hemmati A, Rahmati M, Charoudeh HN. Regulation and modulation of PTEN activity. Mol Biol Rep 2018;45:2869-81. [PMID: 30145641 DOI: 10.1007/s11033-018-4321-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 7.6] [Reference Citation Analysis]
24 Gu Y, Chow MJ, Kapoor A, Mei W, Jiang Y, Yan J, De Melo J, Seliman M, Yang H, Cutz JC, Bonert M, Major P, Tang D. Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development. Transl Oncol 2018;11:1012-22. [PMID: 29966864 DOI: 10.1016/j.tranon.2018.06.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
25 Wei F, Hao P, Zhang X, Hu H, Jiang D, Yin A, Wen L, Zheng L, He JZ, Mei W, Zeng H, Tang D. Etoposide-induced DNA damage affects multiple cellular pathways in addition to DNA damage response. Oncotarget 2018;9:24122-39. [PMID: 29844877 DOI: 10.18632/oncotarget.24517] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
26 Kotelevets L, Scott MGH, Chastre E. Targeting PTEN in Colorectal Cancers. Targeted Therapy of Colorectal Cancer Subtypes 2018. [DOI: 10.1007/978-3-030-02771-1_5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
27 Tamiya H, Kim H, Klymenko O, Kim H, Feng Y, Zhang T, Han JY, Murao A, Snipas SJ, Jilaveanu L, Brown K, Kluger H, Zhang H, Iwai K, Ronai ZA. SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth. J Clin Invest 2018;128:517-30. [PMID: 29227283 DOI: 10.1172/JCI95410] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
28 Ojo D, Seliman M, Tang D. Signatures derived from increase in SHARPIN gene copy number are associated with poor prognosis in patients with breast cancer. BBA Clin 2017;8:56-65. [PMID: 28879097 DOI: 10.1016/j.bbacli.2017.07.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
29 Zhuang T, Yu S, Zhang L, Yang H, Li X, Hou Y, Liu Z, Shi Y, Wang W, Yu N, Li A, Li X, Li X, Niu G, Xu J, Hasni MS, Mu K, Wang H, Zhu J. SHARPIN stabilizes estrogen receptor α and promotes breast cancer cell proliferation. Oncotarget 2017;8:77137-51. [PMID: 29100376 DOI: 10.18632/oncotarget.20368] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
30 Khan MH, Salomaa SI, Jacquemet G, Butt U, Miihkinen M, Deguchi T, Kremneva E, Lappalainen P, Humphries MJ, Pouwels J. The Sharpin interactome reveals a role for Sharpin in lamellipodium formation via the Arp2/3 complex. J Cell Sci 2017;130:3094-107. [PMID: 28775156 DOI: 10.1242/jcs.200329] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
31 Lin X, Wei F, Major P, Al-Nedawi K, Al Saleh HA, Tang D. Microvesicles Contribute to the Bystander Effect of DNA Damage. Int J Mol Sci 2017;18:E788. [PMID: 28387728 DOI: 10.3390/ijms18040788] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
32 Peuhu E, Kaukonen R, Lerche M, Saari M, Guzmán C, Rantakari P, De Franceschi N, Wärri A, Georgiadou M, Jacquemet G, Mattila E, Virtakoivu R, Liu Y, Attieh Y, Silva KA, Betz T, Sundberg JP, Salmi M, Deugnier MA, Eliceiri KW, Ivaska J. SHARPIN regulates collagen architecture and ductal outgrowth in the developing mouse mammary gland. EMBO J 2017;36:165-82. [PMID: 27974362 DOI: 10.15252/embj.201694387] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
33 Tanaka Y, Tateishi K, Nakatsuka T, Kudo Y, Takahashi R, Miyabayashi K, Yamamoto K, Asaoka Y, Ijichi H, Tateishi R, Shibahara J, Fukayama M, Ishizawa T, Hasegawa K, Kokudo N, Koike K. Sharpin promotes hepatocellular carcinoma progression via transactivation of Versican expression. Oncogenesis 2016;5:e277. [PMID: 27941932 DOI: 10.1038/oncsis.2016.76] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
34 Wang X, Huang H, Young KH. The PTEN tumor suppressor gene and its role in lymphoma pathogenesis. Aging (Albany NY) 2015;7:1032-49. [PMID: 26655726 DOI: 10.18632/aging.100855] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
35 Barrow-McGee R, Kishi N, Joffre C, Ménard L, Hervieu A, Bakhouche BA, Noval AJ, Mai A, Guzmán C, Robbez-Masson L, Iturrioz X, Hulit J, Brennan CH, Hart IR, Parker PJ, Ivaska J, Kermorgant S. Beta 1-integrin-c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes. Nat Commun 2016;7:11942. [PMID: 27336951 DOI: 10.1038/ncomms11942] [Cited by in Crossref: 60] [Cited by in F6Publishing: 69] [Article Influence: 8.6] [Reference Citation Analysis]
36 Ikeda F. Linear ubiquitination signals in adaptive immune responses. Immunol Rev 2015;266:222-36. [PMID: 26085218 DOI: 10.1111/imr.12300] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 8.4] [Reference Citation Analysis]
37 De Franceschi N, Peuhu E, Parsons M, Rissanen S, Vattulainen I, Salmi M, Ivaska J, Pouwels J. Mutually Exclusive Roles of SHARPIN in Integrin Inactivation and NF-κB Signaling. PLoS One 2015;10:e0143423. [PMID: 26600301 DOI: 10.1371/journal.pone.0143423] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
38 Chien SJ, Silva KA, Kennedy VE, HogenEsch H, Sundberg JP. The pathogenesis of chronic eosinophilic esophagitis in SHARPIN-deficient mice. Exp Mol Pathol 2015;99:460-7. [PMID: 26321245 DOI: 10.1016/j.yexmp.2015.08.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
39 Jerde TJ. Phosphatase and Tensin Homologue: Novel Regulation by Developmental Signaling. J Signal Transduct 2015;2015:282567. [PMID: 26339505 DOI: 10.1155/2015/282567] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
40 Bermúdez Brito M, Goulielmaki E, Papakonstanti EA. Focus on PTEN Regulation. Front Oncol 2015;5:166. [PMID: 26284192 DOI: 10.3389/fonc.2015.00166] [Cited by in Crossref: 75] [Cited by in F6Publishing: 85] [Article Influence: 9.4] [Reference Citation Analysis]
41 De Melo J, Tang D. Elevation of SIPL1 (SHARPIN) Increases Breast Cancer Risk. PLoS One 2015;10:e0127546. [PMID: 25992689 DOI: 10.1371/journal.pone.0127546] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
42 Dillon LM, Miller TW. Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets 2014;15:65-79. [PMID: 24387334 DOI: 10.2174/1389450114666140106100909] [Cited by in Crossref: 158] [Cited by in F6Publishing: 166] [Article Influence: 17.6] [Reference Citation Analysis]
43 Hopkins BD, Hodakoski C, Barrows D, Mense SM, Parsons RE. PTEN function: the long and the short of it. Trends Biochem Sci 2014;39:183-90. [PMID: 24656806 DOI: 10.1016/j.tibs.2014.02.006] [Cited by in Crossref: 186] [Cited by in F6Publishing: 194] [Article Influence: 20.7] [Reference Citation Analysis]
44 Becker-Kojić ZA, Ureña-Peralta JR, Zipančić I, Rodriguez-Jiménez FJ, Rubio MP, Stojković P, Roselló MG, Stojković M. Activation by ACA induces pluripotency in human blood progenitor cells. Bull Exp Biol Med 2013;155:552-67. [PMID: 24143386 DOI: 10.1007/s10517-013-2196-z] [Reference Citation Analysis]
45 Gabriel K, Ingram A, Austin R, Kapoor A, Tang D, Majeed F, Qureshi T, Al-Nedawi K. Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer. PLoS One. 2013;8:e70047. [PMID: 23936141 DOI: 10.1371/journal.pone.0070047] [Cited by in Crossref: 89] [Cited by in F6Publishing: 94] [Article Influence: 8.9] [Reference Citation Analysis]
46 Shi Y, Paluch BE, Wang X, Jiang X. PTEN at a glance. J Cell Sci. 2012;125:4687-4692. [PMID: 23223894 DOI: 10.1242/jcs.093765] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 7.5] [Reference Citation Analysis]
47 Yan J, Wong N, Hung C, Chen WX, Tang D. Contactin-1 reduces E-cadherin expression via activating AKT in lung cancer. PLoS One. 2013;8:e65463. [PMID: 23724143 DOI: 10.1371/journal.pone.0065463] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
48 Hu L, Wang W, Cai J, Luo J, Huang Y, Xiong S, Li W, Guo M. Aberrant expression of ZNF268 alters the growth and migration of ovarian cancer cells. Oncol Lett 2013;6:49-54. [PMID: 23946776 DOI: 10.3892/ol.2013.1318] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
49 Wang Z, Potter CS, Sundberg JP, Hogenesch H. SHARPIN is a key regulator of immune and inflammatory responses. J Cell Mol Med 2012;16:2271-9. [PMID: 22452937 DOI: 10.1111/j.1582-4934.2012.01574.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
50 Boosani CS, Agrawal DK. PTEN modulators: a patent review. Expert Opin Ther Pat 2013;23:569-80. [PMID: 23379765 DOI: 10.1517/13543776.2013.768985] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
51 Ruscetti MA, Wu H. PTEN in Prostate Cancer. Prostate Cancer 2013. [DOI: 10.1007/978-1-4614-6828-8_4] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
52 Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13:283-296. [PMID: 22473468 DOI: 10.1038/nrm3330] [Cited by in Crossref: 1288] [Cited by in F6Publishing: 1398] [Article Influence: 117.1] [Reference Citation Analysis]
53 Georgescu MM. PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer. 2010;1:1170-1177. [PMID: 21779440 DOI: 10.1177/1947601911407325] [Cited by in Crossref: 261] [Cited by in F6Publishing: 278] [Article Influence: 21.8] [Reference Citation Analysis]
54 He L, Fan C, Kapoor A, Ingram AJ, Rybak AP, Austin RC, Dickhout J, Cutz JC, Scholey J, Tang D. α-Mannosidase 2C1 attenuates PTEN function in prostate cancer cells. Nat Commun 2011;2:307. [PMID: 21556061 DOI: 10.1038/ncomms1309] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
55 Rantala JK, Pouwels J, Pellinen T, Veltel S, Laasola P, Mattila E, Potter CS, Duffy T, Sundberg JP, Kallioniemi O, Askari JA, Humphries MJ, Parsons M, Salmi M, Ivaska J. SHARPIN is an endogenous inhibitor of β1-integrin activation. Nat Cell Biol 2011;13:1315-24. [PMID: 21947080 DOI: 10.1038/ncb2340] [Cited by in Crossref: 160] [Cited by in F6Publishing: 165] [Article Influence: 13.3] [Reference Citation Analysis]
56 Zak DE, Schmitz F, Gold ES, Diercks AH, Peschon JJ, Valvo JS, Niemistö A, Podolsky I, Fallen SG, Suen R, Stolyar T, Johnson CD, Kennedy KA, Hamilton MK, Siggs OM, Beutler B, Aderem A. Systems analysis identifies an essential role for SHANK-associated RH domain-interacting protein (SHARPIN) in macrophage Toll-like receptor 2 (TLR2) responses. Proc Natl Acad Sci U S A 2011;108:11536-41. [PMID: 21709223 DOI: 10.1073/pnas.1107577108] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 5.0] [Reference Citation Analysis]